CHANGE OF REGISTERED OFFICE AND PRINCIPAL PLACE OF BUSINESS

Melbourne, Australia – 21 February 2024: Percheron Therapeutics Limited, an international biotechnology company focused on the development of novel therapies for rare diseases, is pleased to advise, in accordance with ASX Listing Rule 3.14, that its registered office and principal place of business has changed, with immediate effect, to:

L30, Collins Place,
35 Collins Street,
Melbourne, VIC 3000
Australia

The Company's other contact details remain unchanged:

Telephone: +61 3 9827 8999
Email: info@PercheronTx.com
Website: www.PercheronTx.com

"Our new office places us in closer proximity to our investors, bankers, and other stakeholders," commented Percheron CEO, Dr James Garner. "The move represents a material cost savings in comparison to our previous location, consistent with the company's focus on prudent financial management, and the transition has been straightforward, with no impact on our business activities. Moreover, the serviced office model provides much greater flexibility as our business evolves, allowing us to access space and resources only as we need them."

~ ENDS ~

About Percheron Therapeutics Limited

Percheron Therapeutics Limited [ASX: PER | US OTC: ATHJY | FSE: AWY] is a publicly listed biotechnology company focused on the development and commercialisation of novel therapies for rare diseases. The Company's lead program is ATL1102, an antisense oligonucleotide targeting the CD49d receptor. ATL1102 is currently the subject of an ongoing international phase IIb clinical trial for the treatment of non-ambulant patients with Duchenne Muscular Dystrophy (DMD), for which data is expected in 2H CY2024. The drug has previously reported promising results from an exploratory phase IIa study in the same population and has been awarded orphan drug designation (ODD) and rare pediatric disease designation (RPDD) by the US FDA.

For more information, please contact info@PercheronTx.com.

This announcement has been authorized for release to the Australian Securities Exchange by the Board of Directors.